Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Phase 1
Terminated
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Pellficure Pharmaceuticals, Inc
- Target Recruit Count
- 7
- Registration Number
- NCT04677855
- Locations
- ๐บ๐ธ
Nebraska Cancer Specialist, Omaha, Nebraska, United States
๐บ๐ธUniversity of Michigan, Ann Arbor, Michigan, United States
๐ฆ๐บSt. George Private Hospital, Kogarah, New South Wales, Australia
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Drug: PCUR - 101
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Pellficure Pharmaceuticals, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT03137758
- Locations
- ๐บ๐ธ
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
๐บ๐ธKarmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธJohns Hopkins University School of Medicine, Baltimore, Maryland, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath